- Home
- MDCX vs COEP Comparison
MDCX vs COEP Comparison
Compare MDCX & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- COEP
- Stock Information
- Founded
- MDCX 2008
- COEP 2017
- Country
- MDCX Canada
- COEP United States
- Employees
- MDCX N/A
- COEP N/A
- Industry
- MDCX
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDCX
- COEP Health Care
- Exchange
- MDCX Nasdaq
- COEP Nasdaq
- Market Cap
- MDCX 33.8M
- COEP 32.4M
- IPO Year
- MDCX N/A
- COEP N/A
- Fundamental
- Price
- MDCX $4.00
- COEP $10.52
- Analyst Decision
- MDCX Strong Buy
- COEP
- Analyst Count
- MDCX 1
- COEP 0
- Target Price
- MDCX $10.00
- COEP N/A
- AVG Volume (30 Days)
- MDCX 41.4K
- COEP 108.7K
- Earning Date
- MDCX 01-01-0001
- COEP 03-25-2025
- Dividend Yield
- MDCX N/A
- COEP N/A
- EPS Growth
- MDCX N/A
- COEP N/A
- EPS
- MDCX N/A
- COEP N/A
- Revenue
- MDCX N/A
- COEP N/A
- Revenue This Year
- MDCX N/A
- COEP N/A
- Revenue Next Year
- MDCX N/A
- COEP N/A
- P/E Ratio
- MDCX N/A
- COEP N/A
- Revenue Growth
- MDCX N/A
- COEP N/A
- 52 Week Low
- MDCX $1.80
- COEP $2.31
- 52 Week High
- MDCX $4.39
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- COEP 48.65
- Support Level
- MDCX N/A
- COEP $9.27
- Resistance Level
- MDCX N/A
- COEP $12.95
- Average True Range (ATR)
- MDCX 0.00
- COEP 1.59
- MACD
- MDCX 0.00
- COEP -0.33
- Stochastic Oscillator
- MDCX 0.00
- COEP 38.56
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.